The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Somnath Chatterjee, Promoter, Chairman and Joint Managing Director of Suraksha Diagnostic Ltd, bought 7,590 equity shares through an open market purchase on 13 June 2025. His holding in the company rose from 25,99,689 shares to 26,07,279 shares, taking his stake to about 5.01% of the paid-up equity capital. The disclosure was filed under Regulation 29(2) of SEBI's Takeover Regulations, triggered because the acquisition crossed the 5% disclosure threshold. The total paid-up equity capital of the company remains unchanged at 5,20,80,758 shares of Rs 2 each.
This is a small but confidence-signalling purchase by the promoter in the open market, indicating continued faith in the company. While the quantum is minor, the timing (just crossing the 5% disclosure mark) shows the promoter is incrementally adding to his position rather than trimming it.